Enoch Aninagyei , Reuben Ayivor-Djanie , Jones Gyamfi , Marfo Edward Aboagye , Grace Semabia Kpeli , William Kwabena Ampofo , John Owusu Gyapong , Kwabena Obeng Duedu
{"title":"加纳沃尔特地区接种疫苗前的 SARS-CoV-2 抗体血清流行率","authors":"Enoch Aninagyei , Reuben Ayivor-Djanie , Jones Gyamfi , Marfo Edward Aboagye , Grace Semabia Kpeli , William Kwabena Ampofo , John Owusu Gyapong , Kwabena Obeng Duedu","doi":"10.1016/j.ijregi.2024.01.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Before administration of the first dose of the AstraZeneca 2019 SARS-CoV-2 vaccine to selected prioritized groups in the Volta regional capital of Ghana, we determined the pre-vaccination status of prospective recipients and established the baseline exposure status 1 year after the first case was reported.</p></div><div><h3>Methods</h3><p>After informed consent, blood samples were collected for the detection of SARS-CoV-2 immunoglobulin (Ig) M/IgG antibodies using rapid diagnostic test kits. A total of 409 individuals (mean age 27 years) consented and participated in the study, comprising 70% students and others were health staff and educators who presented themselves for vaccination.</p></div><div><h3>Results</h3><p>The overall exposure rate of SARS-CoV-2 was 12.7% (95% confidence interval [CI] 9.6-16.3). The prevalence of SARS-CoV-2 IgM and IgG were 4.2% (95% CI 2.4-6.6) and 5.6% (95% CI 3.6-8.3), respectively. IgM and IgG were detected in 2.9% (95% CI 1.5-5.1) of the respondents. The exposure rates were higher in participants over 40 years old (15.5%). Participants without a history of COVID-19–like symptoms had an exposure rate of 13.0% and those without any chronic diseases was 13.2%.</p></div><div><h3>Conclusion</h3><p>Pre-vaccination exposure was relatively low and underscored the need for vaccination i to increase protection in communities and disease outcomes.</p></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772707624000079/pdfft?md5=2d01d4bb57b1dd28d6d6c3f9359df221&pid=1-s2.0-S2772707624000079-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana\",\"authors\":\"Enoch Aninagyei , Reuben Ayivor-Djanie , Jones Gyamfi , Marfo Edward Aboagye , Grace Semabia Kpeli , William Kwabena Ampofo , John Owusu Gyapong , Kwabena Obeng Duedu\",\"doi\":\"10.1016/j.ijregi.2024.01.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Before administration of the first dose of the AstraZeneca 2019 SARS-CoV-2 vaccine to selected prioritized groups in the Volta regional capital of Ghana, we determined the pre-vaccination status of prospective recipients and established the baseline exposure status 1 year after the first case was reported.</p></div><div><h3>Methods</h3><p>After informed consent, blood samples were collected for the detection of SARS-CoV-2 immunoglobulin (Ig) M/IgG antibodies using rapid diagnostic test kits. A total of 409 individuals (mean age 27 years) consented and participated in the study, comprising 70% students and others were health staff and educators who presented themselves for vaccination.</p></div><div><h3>Results</h3><p>The overall exposure rate of SARS-CoV-2 was 12.7% (95% confidence interval [CI] 9.6-16.3). The prevalence of SARS-CoV-2 IgM and IgG were 4.2% (95% CI 2.4-6.6) and 5.6% (95% CI 3.6-8.3), respectively. IgM and IgG were detected in 2.9% (95% CI 1.5-5.1) of the respondents. The exposure rates were higher in participants over 40 years old (15.5%). Participants without a history of COVID-19–like symptoms had an exposure rate of 13.0% and those without any chronic diseases was 13.2%.</p></div><div><h3>Conclusion</h3><p>Pre-vaccination exposure was relatively low and underscored the need for vaccination i to increase protection in communities and disease outcomes.</p></div>\",\"PeriodicalId\":73335,\"journal\":{\"name\":\"IJID regions\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772707624000079/pdfft?md5=2d01d4bb57b1dd28d6d6c3f9359df221&pid=1-s2.0-S2772707624000079-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJID regions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772707624000079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJID regions","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772707624000079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana
Objectives
Before administration of the first dose of the AstraZeneca 2019 SARS-CoV-2 vaccine to selected prioritized groups in the Volta regional capital of Ghana, we determined the pre-vaccination status of prospective recipients and established the baseline exposure status 1 year after the first case was reported.
Methods
After informed consent, blood samples were collected for the detection of SARS-CoV-2 immunoglobulin (Ig) M/IgG antibodies using rapid diagnostic test kits. A total of 409 individuals (mean age 27 years) consented and participated in the study, comprising 70% students and others were health staff and educators who presented themselves for vaccination.
Results
The overall exposure rate of SARS-CoV-2 was 12.7% (95% confidence interval [CI] 9.6-16.3). The prevalence of SARS-CoV-2 IgM and IgG were 4.2% (95% CI 2.4-6.6) and 5.6% (95% CI 3.6-8.3), respectively. IgM and IgG were detected in 2.9% (95% CI 1.5-5.1) of the respondents. The exposure rates were higher in participants over 40 years old (15.5%). Participants without a history of COVID-19–like symptoms had an exposure rate of 13.0% and those without any chronic diseases was 13.2%.
Conclusion
Pre-vaccination exposure was relatively low and underscored the need for vaccination i to increase protection in communities and disease outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
